全文获取类型
收费全文 | 232571篇 |
免费 | 51620篇 |
国内免费 | 3549篇 |
专业分类
耳鼻咽喉 | 2728篇 |
儿科学 | 7306篇 |
妇产科学 | 2257篇 |
基础医学 | 30773篇 |
口腔科学 | 9286篇 |
临床医学 | 28582篇 |
内科学 | 44027篇 |
皮肤病学 | 6391篇 |
神经病学 | 24244篇 |
特种医学 | 9802篇 |
外国民族医学 | 39篇 |
外科学 | 26636篇 |
综合类 | 18190篇 |
现状与发展 | 23篇 |
一般理论 | 11篇 |
预防医学 | 12889篇 |
眼科学 | 3344篇 |
药学 | 19398篇 |
74篇 | |
中国医学 | 12669篇 |
肿瘤学 | 29071篇 |
出版年
2024年 | 246篇 |
2023年 | 2170篇 |
2022年 | 4068篇 |
2021年 | 6971篇 |
2020年 | 10936篇 |
2019年 | 15630篇 |
2018年 | 14937篇 |
2017年 | 16613篇 |
2016年 | 16040篇 |
2015年 | 15711篇 |
2014年 | 19519篇 |
2013年 | 22182篇 |
2012年 | 17251篇 |
2011年 | 17626篇 |
2010年 | 15041篇 |
2009年 | 11128篇 |
2008年 | 11581篇 |
2007年 | 10443篇 |
2006年 | 9625篇 |
2005年 | 8809篇 |
2004年 | 7750篇 |
2003年 | 7044篇 |
2002年 | 6197篇 |
2001年 | 5063篇 |
2000年 | 3499篇 |
1999年 | 1933篇 |
1998年 | 1429篇 |
1997年 | 1206篇 |
1996年 | 1003篇 |
1995年 | 902篇 |
1994年 | 709篇 |
1993年 | 549篇 |
1992年 | 489篇 |
1991年 | 454篇 |
1990年 | 382篇 |
1989年 | 329篇 |
1988年 | 319篇 |
1987年 | 274篇 |
1986年 | 216篇 |
1985年 | 254篇 |
1984年 | 223篇 |
1983年 | 165篇 |
1982年 | 164篇 |
1981年 | 163篇 |
1980年 | 129篇 |
1979年 | 121篇 |
1978年 | 67篇 |
1977年 | 42篇 |
1976年 | 49篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
72.
Stephanie Kay Kolar 《Addiction Research & Theory》2016,24(1):25-31
Aims: Relapse rates among cigarette smokers are high. Few studies have examined time-to-relapse using survival analysis in racially/ethnically diverse smokers and initial abstinence criteria have been inconsistent or unspecified. This study compared survival curves using two common definitions of initial abstinence. We hypothesized greater relapse rates among participants abstinent for only 24 hours (h) at the end-of-therapy (EOT) compared with 7 days. Methods: Adult smokers (59% Black, 22% Hispanic and 17% White) received 8-sessions of group cognitive behavioural therapy (CBT) plus transdermal nicotine patches and were assessed monthly up to 12 months post-EOT. Participants reporting abstinence (7-day point prevalence abstinence [ppa] or 24-h ppa) at the EOT were included in Kaplan–Meier curves. Results: Of 301 participants, 120 (40%) reported 7-day ppa at the EOT and an additional 29 (10%) reported 24-h ppa only. Over the 12-month follow-up period, nearly 50% remained abstinent. Of those who resumed smoking, most relapses occurred within the first three months. Survival curves indicated that median survival was 207 and 225 days for 7-day and 24-h definitions of abstinence, respectively. The difference in time-to-relapse between participants abstinent for 24?h at the EOT versus 7-days was not significant (p?=?0.14). Conclusions: Operationalization of initial abstinence is important for relapse analyses and comparisons of survival curves across samples. Participants reported high rates of abstinence and relapse rates were relatively low. Contrary to expectations, 24-h ppa at the EOT was not associated with greater relapse than 7-day abstinence. This suggests either measure may be utilized in relapse prevention research in racially/ethnically diverse treatment-seekers. 相似文献
73.
74.
我国属胃癌高发国家,且以进展期胃癌为主。以手术和化疗为主的多学科治疗无法有效改善晚期胃癌患者的预后。近年来,免疫检查点抑制剂类药物的疗效在诸多癌症中得到了证实,因此,该类药物在胃癌中的治疗效果也受到了广泛的关注。本文对近年来的相关研究成果进行综述,全面介绍了免疫检查点抑制剂类药物在胃癌治疗中的临床应用情况、联合用药情况以及不良反应。对于其他治疗均失败的晚期胃癌患者,PD-1抑制剂是一个可行的治疗选项,其代表药物派姆单抗是目前唯一被美国食品药品监督管理局批准应用于胃癌治疗的免疫抑制剂类药物,而我国国家食品药品监督管理总局尚未批准任何此类药物应用于胃癌的临床治疗。如何进一步提高治疗的客观缓解率,将会是后续临床和基础研究的一大焦点。 相似文献
75.
Peng‐fei Lei Shi‐long Su Ling‐yu Kong Cheng‐gong Wang Da Zhong Yi‐he Hu 《Orthopaedic Surgery》2019,11(5):914-920
Three‐dimensional (3D) printing technology, virtual reality, and augmented reality technology have been used to help surgeons to complete complex total hip arthroplasty, while their respective shortcomings limit their further application. With the development of technology, mixed reality (MR) technology has been applied to improve the success rate of complicated hip arthroplasty because of its unique advantages. We presented a case of a 59‐year‐old man with an intertrochanteric fracture in the left femur, who had received a prior left hip fusion. After admission to our hospital, a left total hip arthroplasty was performed on the patient using a combination of MR technology and 3D printing technology. Before surgery, 3D reconstruction of a certain bony landmark exposed in the surgical area was first performed. Then a veneer part was designed according to the bony landmark and connected to a reference registration landmark outside the body through a connecting rod. After that, the series of parts were made into a holistic reference registration instrument using 3D printing technology, and the patient's data for bone and surrounding tissue, along with digital 3D information of the reference registration instrument, were imported into the head‐mounted display (HMD). During the operation, the disinfected reference registration instrument was installed on the selected bony landmark, and then the automatic real‐time registration was realized by HMD through recognizing the registration landmark on the reference registration instrument, whereby the patient's virtual bone and other anatomical structures were quickly and accurately superimposed on the real body of the patient. To the best of our knowledge, this is the first report to use MR combined with 3D printing technology in total hip arthroplasty. 相似文献
76.
77.
78.
79.
80.